Genentech taps Imbio to develop AI programs for scanning lung diseases

lung ct scan
Imbio’s programs take CT scans and visualize lung tissue density, while mapping out the areas that may be trapping air and quantifying measures related to emphysema and chronic obstructive pulmonary disease. (Getty Images)

Genentech has inked a multiyear partnership with Imbio to develop artificial-intelligence-powered imaging diagnostics for lung diseases for use within the Roche division’s clinical trials, as well as more broadly by physicians.

Imbio’s programs take chest CT scans and provide a visual overlay of lung tissue density, map out the areas of the organ that may be trapping air and quantify measures related to emphysema and chronic obstructive pulmonary disease, including in smokers at risk for lung cancer. These programs have been cleared by the FDA and have received CE marks.

The company also uses machine vision algorithms to analyze the texture of the lungs to spot abnormalities and help diagnose interstitial lung diseases and fibrosis. This has received a CE mark, but is for investigational use only in the U.S.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

"Imaging biomarkers have the potential to significantly improve patient diagnosis, selection and understanding of response to therapy," said James Sabry, global head of Roche Pharma Partnering. "This collaboration, which combines Imbio's expertise in imaging biomarkers with Genentech's pulmonary disease expertise, has the potential to enhance drug development and deliver more personalized healthcare."

RELATED: GE Healthcare to add startup's CT lung density analysis to its new 'Health Cloud'

The partnership aims to develop a new set of unique pulmonary imaging solutions, while Imbio will continue to work on its own portfolio of AI offerings. Financial considerations were not disclosed.

“This collaboration is a great example of Imbio's strategy to meet the growing interest by medical device and pharmaceutical companies in using imaging biomarkers and imaging AI to facilitate diagnosis of respiratory diseases," CEO David Hannes said.

Early this year, Imbio signed a deal with U.K.-based platform provider Wellbeing Software to deploy its lung density-mapping software to providers in the National Health Service.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.